文献速递甲状腺核医学核素与放射性配体治疗

[211At]NaAt作为靶向α疗法治疗放射性碘难治性甲状腺癌患者的首次人体研究(Alpha-T1试验)

First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial).
PubMed 文献 · J Nucl Med · 2025-12-03

这项首次人体前瞻性临床试验纳入11例转移性放射性碘难治性分化型甲状腺癌患者,单次静脉给予[211At]NaAt,剂量按改良3+3设计递增至1.25、2.5和3.5 MBq/kg。3.5 MBq/kg组6例中3例出现剂量限制性毒性(持续超过1周的3级血液学毒性)。结论认为该靶向α疗法耐受良好并显示初步疗效,支持进一步临床研究。

要点

  • 3.5 MBq/kg组6例中3例出现剂量限制性毒性,为持续超过1周的3级淋巴细胞减少或白细胞减少。
  • 2.5 MBq/kg组3例中1例(33%)、3.5 MBq/kg组5例中2例(40%)促甲状腺激素刺激后甲状腺球蛋白降低超过50%。
  • 6个月时CT评估9例(90%)疾病稳定、1例(10%)疾病进展。

核心结论

  • [211At]NaAt靶向α疗法在放射性碘难治性分化型甲状腺癌患者中耐受良好并显示初步疗效,支持进一步临床研究。

研究设计与样本

  • 首次人体前瞻性临床试验(Alpha-T1试验),纳入11例转移性放射性碘难治性分化型甲状腺癌患者。
  • 在重组人促甲状腺激素刺激和限碘饮食条件下单次静脉给予[211At]NaAt,剂量递增采用改良3+3设计,剂量为1.25 MBq/kg(2例)、2.5 MBq/kg(3例)和3.5 MBq/kg(6例)。
  • 主要终点为按不良事件通用术语标准5.0版评估的不良事件和剂量限制性毒性;次要终点包括药代动力学、吸收剂量和疗效评估。

主要发现

  • 3.5 MBq/kg组6例中3例发生剂量限制性毒性,为持续超过1周的3级血液学毒性(淋巴细胞减少或白细胞减少)。
  • 其他主要不良事件包括唾液腺肿胀(以2级为主)、口干(1级和2级)、恶心(2级)、食欲下降(2级)和呕吐(2级)。
  • 重组人促甲状腺激素刺激后甲状腺球蛋白降低超过50%见于2.5 MBq/kg组3例中的1例(33%)和3.5 MBq/kg组5例中的2例(40%)。
  • 6个月时CT评估显示9例(90%)疾病稳定、1例(10%)疾病进展。
  • 131I SPECT显像显示唯一接受1.25 MBq/kg治疗的患者疾病稳定;2.5 MBq/kg组3例中1例(33%)部分缓解、2例(67%)疾病稳定;3.5 MBq/kg组5例中完全缓解、部分缓解和疾病进展各1例(20%),2例(40%)疾病稳定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

211At, a cyclotron-produced α-emitter, has attracted interest as a potential alternative to radioactive iodine (RAI) because of its superior cytotoxic properties. This first-in-human prospective clinical trial aimed to evaluate the safety and preliminary efficacy of [211At]NaAt in patients with differentiated thyroid cancer (DTC). Methods: Eleven patients with metastatic RAI-refractory DTC were enrolled in this study. A single intravenous dose of [211At]NaAt was administered in the setting of recombinant human thyroid-stimulating hormone stimulation and an iodine-restricted diet. Dose escalation followed a modified 3 + 3 design, with doses of 1.25 (n = 2), 2.5 (n = 3), and 3.5 MBq/kg (n = 6). The primary endpoint was the assessment of adverse events using Common Terminology Criteria for Adverse Events version 5.0 guidelines and dose-limiting toxicities. Secondary endpoints included evaluation of pharmacokinetics, absorbed dose, and therapeutic efficacy. Results: Dose-limiting toxicities occurred in 3 of 6 patients who received 3.5 MBq/kg, consisting of grade 3 hematologic toxicity (lymphopenia or leukopenia) lasting for more than 1 wk. Other major adverse events included salivary gland swelling (predominantly grade 2), xerostomia (grades 1 and 2), nausea (grade 2), decreased appetite (grade 2), and vomiting (grade 2). A reduction of greater than 50% in recombinant human thyroid-stimulating hormone-stimulated thyroglobulin levels was observed in 1 of 3 patients (33%) who received 2.5 MBq/kg and 2 of 5 patients (40%) who received 3.5 MBq/kg. At 6 mo, CT-based evaluation showed stable disease (SD) in 9 patients (90%) and progressive disease in 1 patient (10%). 131I SPECT imaging revealed SD in the only patient who received 1.25 MBq/kg. Of the 3 patients treated with 2.5 MBq/kg, a partial response was seen in 1 patient (33%) and SD in 2 patients (67%). Of the 5 patients who received 3.5 MBq/kg, complete response, partial response, and progressive disease were noted in 1 patient (20%) each, and SD was found in 2 patients (40%). Conclusion: Targeted α-therapy with [211At]NaAt was well tolerated and showed preliminary efficacy in patients with RAI-refractory DTC, supporting further clinical investigations.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Watabe T, Mukai K, Naka S, et al. First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial). J Nucl Med. 2025. PMID: 40998730. doi:10.2967/jnumed.125.270810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。